Artificial organs are human-made bioartificial devices, which are implanted or integrated into individuals to replace or support natural organs. These include artificial heart, kidney, pancreas, and cochlear implants. Biocompatible materials such as polymers (polyurethane, polysulfone, and porous polypropylene), biologics, ceramics, and metals are used to develop artificial organs. These organs are incorporated with different technologies like sensors, biomaterials, and innovative delivery systems. Artificial organs perform the function of the natural organ and help the patient to live a quality life. In few cases, artificial organs are capable of eliminating the need for organ transplantation altogether.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Assumptions

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

A glance at parent market: Artificial organs

PART 05: An overview of pancreas and diabetes

Pancreas

Diabetes

Insulin overview

PART 06: Need for better systems in the management of

diabetes

PART 07: Artificial pancreas device system

Technology landscape

PART 08: Initiatives for the development of APDS

Juvenile Diabetes Research Foundation (JDRF) initiative

— 2006

European Commission’s AP@home project — 2010

Centre for bio-inspired technology — Bionic pancreas

Harvard University — 2014

PART 09: FDA’s role in fostering the development of APDS

Rapid response to preliminary study plans

Interactive review of investigational device exemption

study plans

Guidance and standards for researchers and industry

PART 10: Reimbursement scenario

Australia

Germany

UK

US

PART 11: Key clinical trials

PART 12: Market landscape

Market overview

Five forces analysis

PART 13: Market segmentation by categories

TSDS

NTSDS

CTRS

CTTS

PART 14: Geographical segmentation

APDS market in Americas

APDS market in EMEA

APDS market in APAC

PART 15: Market drivers

Growing technological integration fuelling the market

growth

Increasing initiatives of research organizations fostering

innovation in the market

Increasing prevalence of diabetes fuelling the need for

effective devices

PART 16: Impact of drivers

PART 17: Market challenges

Lack of smart control algorithms affecting the adoption

rate of existing APDS

Low penetration rates affecting the market growth

Lab-grown pancreatic cell transplant as a potential

treatment alternative hindering the growth prospects

PART 18: Impact of drivers and challenges

PART 19: Market trends

Increasing focus on closed loop systems

Growing demand for remote monitoring applications

Focus of new entrants on the development of novel

APDS

PART 20: Vendor landscape

Competitive scenario

PART 21: Key vendor analysis

Medtronic

Johnson & Johnson

Insulet

Tandem Diabetes Care

Roche

Other prominent vendors

PART 22: Appendix

List of abbreviations

PART 23: Explore Technavio